Why is Profound Medical stock surging today?

Profound Medical's stock experienced a significant surge of 19.0% in after-hours trading following the company's announcement of impressive preliminary revenue results for the third quarter of 2026. Analysts had predicted revenue between $9.8 million and $10.0 million, but Profound exceeded expectations by a substantial margin, reaching approximately 45% to 47% above the Bloomberg mean consensus of $6.78 million.

The company's gross margin was also projected to surpass 70%, highlighting the positive trajectory of its business operations.

The magnitude of the beat was further amplified when considering the company's sequential performance. The preliminary Q3 figure represented a remarkable growth rate of 292% to 300% compared to Q2 2026, and around 85% to 89% growth year-over-year when compared to Q3 2025. CEO and Chairman Arun Menawat emphasized this as a historic milestone for Profound, attributing the surge to the expanding installed base and new customer accounts.

Despite a generally subdued market mood, with major indices like the S&P 500, Dow Jones, and NASDAQ experiencing slight declines, Profound's strong performance stood out. Factors contributing to this positive sentiment included rising Treasury yields, reaching near 5.31% for the 10-year rate, and mounting anticipation of Federal Reserve minutes. These elements made the company's specific catalyst particularly compelling in comparison to other equities.

CEO Menawat's reassurance through a statement highlighting sustained commercial momentum added further weight to the positive outlook. As a result, investors found substantial reasons to re-price the stock sharply higher. The after-hours trading propelled Profound Medical shares toward the upper half of their 52-week range, which spanned between $4.80 and $8.95. The article was produced with AI assistance and subsequently reviewed by an editor.